Levocetirizina Bluefish

Levocetirizine, the active ingredient in Levocetirizina Bluefish, is a H1 receptor antagonist presented as an oral dosage form for oral use. It is employed to relieve symptoms of allergic rhinitis and chronic idiopathic urticaria in adults and children when appropriate. GNH USA supplies Levocetirizina Bluefish as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levocetirizine acts on the histamine‑mediated allergic pathway and is indicated for several allergic conditions.

Allergic rhinitis: reduces sneezing, nasal itching, rhinorrhea and congestion. Chronic idiopathic urticaria: diminishes wheal formation and itching. Allergic conjunctivitis: alleviates eye redness, itching and tearing.

Levocetirizine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Drowsiness or mild sedation. - Dry mouth. - Headache. - Nausea. - Fatigue.

Serious or Rare Side Effects: - Angioedema or swelling of the face, lips, tongue. - Severe skin reactions such as Stevens‑Johnson syndrome. - Anaphylactic reactions requiring immediate medical attention. - Cardiac arrhythmias in susceptible individuals. - Hepatic injury manifested by abnormal liver enzymes.

Before initiating therapy, consider patient‑specific factors and monitor for adverse events.

Renal function assessment: dose adjustment may be needed in severe impairment. Elderly patients: start at the lowest effective dose and monitor sedation. Alcohol consumption: avoid or limit as it may enhance drowsiness. Hypersensitivity history: discontinue if rash or swelling develops. Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation. Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Levocetirizine may interact with other medicines; awareness of the interaction level helps manage risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) that may increase plasma levels. - Alcohol, which can potentiate sedation. - Concurrent use of other sedating antihistamines.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., metoprolol) where plasma concentrations may be altered. - Theophylline, as levocetirizine can modestly increase its levels. - Anticholinergic agents that may enhance dry‑mouth effects.